BOULDER, CO / ACCESSWIRE / June 22, 2023 / Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2023 fourth quarter that ended March 31, 2023.
The Company posted quarterly net revenue of $1.81 million for a quarterly net loss of $93 thousand, or $(0.01) per diluted share. These results compare to net revenue of $1.60 million for a quarterly net loss of $403 thousand, or $(0.03) per diluted share, in the year-ago quarter. Gross margin on net revenue was 56% in the fiscal 2023 fourth quarter and 50% in the fiscal 2022 fourth quarter. Gross margin increased in the current year's fourth quarter compared to last year's fourth quarter due principally to higher operating efficiencies and increased selling prices.
The Company posted twelve months net revenue of $7.35 million for a twelve months net loss of $324 thousand, or $(0.03) per diluted share. These results compare to twelve months net revenue of $7.67 million for a twelve months net loss of $66 thousand, or $(0.01) per diluted share, in the year-ago twelve months. Net loss included extinguishment of debt income of $533 thousand in the year-ago twelve months. Gross margin on net revenue was 55% in the fiscal 2023 twelve months and 49% in the fiscal 2022 twelve months. Gross margin in the fiscal 2022 twelve months was lower due to higher material costs.
"Fiscal 2023 presented significant challenges for us and for the medical device market in general," said Gregory Trudel, President and CEO of Encision Inc. "The company navigated through the ups and downs of the market demand curve as a result of COVID slowdowns and a shortage of healthcare workers. We used that time to strengthen our sales channel and to drive new product development that will deliver benefits in fiscal 2024. We were also able to initiate new collaborative opportunities that will be fruitful for us and our partners in fiscal 2024."
Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2022 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT:
Mala Ray
Encision Inc.
303-444-2600
This email address is being protected from spambots. You need JavaScript enabled to view it.
Encision Inc.
Unaudited Condensed Statements of Operations
(in thousands, except per share information)
| Three Months Ended | Years Ended | |||||||||||||||
| March 31, 2023 | March 31, 2022 | March 31, 2023 | March 31, 2022 | |||||||||||||
Product revenue | $ | 1,801 | $ | 1,568 | $ | 6,885 | $ | 6,914 | ||||||||
Service revenue | 5 | 36 | 464 | 754 | ||||||||||||
Total revenue | 1,806 | 1,604 | 7,349 | 7,668 | ||||||||||||
Product cost of revenue | 786 | 781 | 3,314 | 3,509 | ||||||||||||
Service cost of revenue | 2 | 15 | 2 | 371 | ||||||||||||
Total cost of revenue | 788 | 796 | 3,316 | 3,880 | ||||||||||||
Gross profit | 1,018 | 808 | 4,033 | 3,788 | ||||||||||||
Operating expenses: | ||||||||||||||||
Sales and marketing | 539 | 490 | 2,033 | 2,084 | ||||||||||||
General and administrative | 384 | 387 | 1,487 | 1,381 | ||||||||||||
Research and development | 175 | 334 | 816 | 918 | ||||||||||||
Total operating expenses | 1,098 | 1,211 | 4,336 | 4,383 | ||||||||||||
Operating (loss) income | (80 | ) | (403 | ) | (303 | ) | (595 | ) | ||||||||
Interest expense, extinguishment of debt income and other income, net | (13 | ) | -- | (21 | ) | 529 | ||||||||||
(Loss) income before provision for income taxes | (93 | ) | 1 | (324 | ) | (66 | ) | |||||||||
Provision for income taxes | -- | -- | -- | -- | ||||||||||||
Net (loss) income | $ | (93 | ) | $ | (402 | ) | $ | (324 | ) | $ | (66 | ) | ||||
Net (loss) income per share-basic and diluted | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.03 | ) | $ | (0.01 | ) | ||||
Weighted average number of basic shares | 11,770 | 11,683 | 11,763 | 11,625 | ||||||||||||
Weighted average number of diluted shares | 11,770 | 11,683 | 11,763 | 11,625 | ||||||||||||
Encision Inc.
Unaudited Condensed Balance Sheets
(in thousands)
| March 31, 2023 | March 31, 2022 | |||||||
ASSETS | ||||||||
Cash | $ | 189 | $ | 950 | ||||
Accounts receivable, net | 921 | 948 | ||||||
Inventories, net | 1,899 | 1,584 | ||||||
Prepaid expenses and other assets | 116 | 120 | ||||||
Total current assets | 3,125 | 3,602 | ||||||
Equipment, net | 303 | 189 | ||||||
Right of use asset | 496 | 786 | ||||||
Patents, net | 163 | 181 | ||||||
Other assets | 47 | 34 | ||||||
Total assets | $ | 4,134 | $ | 4,792 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Accounts payable | $ | 253 | $ | 576 | ||||
Secured notes | 44 | 22 | ||||||
Line of credit | 177 | -- | ||||||
Accrued compensation | 218 | 191 | ||||||
Other accrued liabilities | 85 | 125 | ||||||
Accrued lease liability | 354 | 362 | ||||||
Total current liabilities | 1,131 | 1,276 | ||||||
Secured notes | 268 | 206 | ||||||
Accrued lease liability | 240 | 564 | ||||||
Unsecured promissory note | -- | -- | ||||||
Total liabilities | 1,639 | 2,046 | ||||||
Common stock and additional paid-in capital | 24,348 | 24,275 | ||||||
Accumulated (deficit) | (21,853 | ) | (21,529 | ) | ||||
Total shareholders' equity | 2,495 | 2,746 | ||||||
Total liabilities and shareholders' equity | $ | 4,134 | $ | 4,792 | ||||
Encision Inc.
Unaudited Condensed Statements of Cash Flows
(in thousands)
| Years Ended | ||||||||
| March 31, 2023 | March 31, 2022 | |||||||
Operating activities: | ||||||||
Net (loss) income | $ | (324 | ) | $ | (66 | ) | ||
Adjustments to reconcile net (loss) income to cash (used in) operating activities: | ||||||||
Extinguishment of debt income | -- | (533 | ) | |||||
Write-off of tooling | -- | 31 | ||||||
Depreciation and amortization | 87 | 113 | ||||||
Share-based compensation expense | 52 | 41 | ||||||
(Recovery from) doubtful accounts, net | -- | (35 | ) | |||||
Provision for (recovery from) inventory obsolescence, net | 15 | (34 | ) | |||||
Changes in operating assets and liabilities: | ||||||||
Right of use asset, net | (43 | ) | (28 | ) | ||||
Accounts receivable | 27 | 163 | ||||||
Inventories | (330 | ) | (105 | ) | ||||
Prepaid expenses and other assets | (8 | ) | (31 | ) | ||||
Accounts payable | (323 | ) | 187 | |||||
Accrued compensation and other accrued liabilities | (14 | ) | (147 | ) | ||||
Net cash (used in) provided by operating activities | (861 | ) | (444 | ) | ||||
Investing activities: | ||||||||
Acquisition of property and equipment | (173 | ) | (18 | ) | ||||
Patent costs | (10 | ) | (18 | ) | ||||
Net cash (used in) investing activities | (183 | ) | (36 | ) | ||||
Financing activities: | ||||||||
Borrowings from credit facility, net change | 240 | -- | ||||||
Net payments from exercise of stock options | 21 | (31 | ) | |||||
Borrowings from (paydown of) secured notes | 23 | (13 | ) | |||||
Net cash provided by (used in) financing activities | 284 | (44 | ) | |||||
Net (decrease) in cash | (761 | ) | (524 | ) | ||||
Cash, beginning of period | 950 | 1,474 | ||||||
Cash, end of period | $ | 189 | $ | 950 | ||||
| Last Trade: | US$0.39 |
| Daily Change: | 0.04 11.43 |
| Daily Volume: | 6,500 |
| Market Cap: | US$4.630M |
November 15, 2024 August 21, 2024 August 15, 2024 July 15, 2024 February 14, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
